ストックスクリーナーアプリを入手
250.88
0.32%
0.79
前日終値:
$250.09
開ける：
$250.25
24時間の取引高:
635.90K
Relative Volume:
0.64
時価総額：
$37.05B
収益：
$5.02B
当期純損益:
$1.31B
株価収益率:
28.16
EPS:
8.91
ネットキャッシュフロー:
$1.56B
1週間 パフォーマンス:
-0.19%
1か月 パフォーマンス:
-0.32%
6か月 パフォーマンス:
+8.98%
1年 パフォーマンス:
+18.19%
1日の値動き範囲:
$249.60
$253.73
1週間の範囲:
$248.20
$254.03
52週間の値動き範囲:
$179.42
$263.05
Resmed Inc Stock (RMD) Company Profile
RMD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
250.88 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
ISRG
Intuitive Surgical Inc
|
509.49 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
168.59 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ALC
Alcon Inc
|
84.77 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
WST
West Pharmaceutical Services Inc
|
217.95 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-19 | 開始されました | Morgan Stanley | Overweight |
| 2025-01-16 | 開始されました | Goldman | Buy |
| 2025-01-10 | 開始されました | Piper Sandler | Neutral |
| 2024-12-13 | 開始されました | Stifel | Hold |
| 2024-09-24 | 開始されました | Robert W. Baird | Outperform |
| 2024-09-18 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | ダウングレード | Needham | Buy → Hold |
| 2024-06-25 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-06-24 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-29 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | アップグレード | Needham | Hold → Buy |
| 2023-09-05 | ダウングレード | UBS | Buy → Neutral |
| 2023-08-01 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | 開始されました | UBS | Buy |
| 2023-04-14 | 開始されました | Mizuho | Buy |
| 2023-01-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-10-20 | アップグレード | BofA Securities | Neutral → Buy |
| 2022-10-12 | 開始されました | Jefferies | Hold |
| 2022-09-08 | アップグレード | Citigroup | Neutral → Buy |
| 2022-08-15 | ダウングレード | CLSA | Buy → Outperform |
| 2022-08-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2022-08-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | 開始されました | Wolfe Research | Outperform |
| 2022-01-31 | アップグレード | Citigroup | Neutral → Buy |
| 2022-01-31 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-28 | アップグレード | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-01-13 | アップグレード | CLSA | Outperform → Buy |
| 2022-01-13 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | アップグレード | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-10-22 | アップグレード | CLSA | Underperform → Outperform |
| 2021-08-02 | ダウングレード | CLSA | Outperform → Sell |
| 2021-08-02 | ダウングレード | Needham | Buy → Hold |
| 2021-07-28 | アップグレード | Jefferies | Underperform → Hold |
| 2021-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-07-14 | 開始されました | RBC Capital Mkts | Underperform |
| 2021-06-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-06-22 | アップグレード | Macquarie | Neutral → Outperform |
| 2021-06-22 | 開始されました | Robert W. Baird | Neutral |
| 2021-06-21 | 繰り返されました | Needham | Buy |
| 2021-06-16 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2021-06-09 | アップグレード | CLSA | Sell → Outperform |
| 2021-05-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-05-11 | アップグレード | Citigroup | Neutral → Buy |
| 2021-04-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-16 | アップグレード | Needham | Hold → Buy |
| 2020-11-02 | アップグレード | UBS | Neutral → Buy |
| 2020-10-30 | アップグレード | JP Morgan | Underweight → Neutral |
| 2020-10-27 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-05-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2020-02-18 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | 開始されました | CLSA | Underperform |
| 2020-01-31 | ダウングレード | UBS | Buy → Neutral |
| 2020-01-10 | 開始されました | Oppenheimer | Perform |
| 2019-11-22 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | アップグレード | UBS | Neutral → Buy |
| 2019-07-16 | ダウングレード | UBS | Buy → Neutral |
| 2019-05-06 | アップグレード | UBS | Neutral → Buy |
| 2019-04-18 | アップグレード | JP Morgan | Underweight → Neutral |
| 2019-01-25 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-25 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2018-10-26 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | 開始されました | Goldman | Buy |
すべてを表示
Resmed Inc (RMD) 最新ニュース
Is the ResMed share price still cheap? What the numbers say - The Motley Fool Australia
ResMed’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Bi Level Automatic Ventilator Market Is Booming Worldwide 2025-2032 | ResMed Inc., Philips Healthcare, Medtronic Plc - openPR.com
ResMed Stock: Is RMD Outperforming the Healthcare Sector? - MSN
ResMed Inc. (RMD) Investor Outlook: Analyzing Growth Potential Amidst a 6% Upside - DirectorsTalk Interviews
Resmed CEO Michael Farrell sells shares worth $2.01 million By Investing.com - Investing.com South Africa
ResMed: A Mixed Bag for Investors Amid Rising Competition - The Globe and Mail
Resmed CEO Michael Farrell sells shares worth $2.01 million - Investing.com
ResMed CEO Sells Shares Worth $2 Million - MarketScreener
ResMed Inc Reports Change in Beneficial Ownership - TipRanks
ResMed: A Sleeping Giant Hiding In Plain Sight (NYSE:RMD) - Seeking Alpha
Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell? - MSN
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed director Peter Farrell sells $494,640 in stock By Investing.com - Investing.com Nigeria
ResMed director Peter Farrell sells $494,640 in stock - Investing.com Australia
ResMed Inc Director Proposes Sale of Common Shares - TipRanks
Successful Exits - University College Dublin
ResMed (RMD) is a Top-Ranked Growth Stock: Should You Buy? - Yahoo Finance
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD) - GuruFocus
ResMed CFO Sells Shares - marketscreener.com
Resmed Inc Reports Decrease in CDI Issuance for May 2025 - TipRanks
ResMed CFO Executes Stock Sale Under Rule 10b5-1 Plan - TipRanks
ResMed Inc. Officer Files Notice for Proposed Sale of Securities - TipRanks
ResMed’s global general counsel Michael Rider sells $9,994 in shares By Investing.com - Investing.com Nigeria
ResMed’s global general counsel Michael Rider sells $9,994 in shares - Investing.com Australia
Dental Sleep Medicine Market Projected to Witness Massive GrowthResMed Inc., SomnoMed Limited - openPR.com
Citi raises ResMed stock price target to AUD45 citing strong EPS growth - Investing.com Nigeria
Here's why I invested MORE money in ResMed shares last week - MSN
There's Reason For Concern Over ResMed Inc.'s (NYSE:RMD) Price - simplywall.st
Sleep Apnea Oral Appliances MarketGlobal Forecast to 2030 with SomnoMed, Resmed, ProSomnus, DynaFlex, Vivos Therapeutics, and OpenAirway Leading - Yahoo Finance
ResMed Inc. Files Conflict Minerals Disclosure Report for 2024 - TipRanks
Actigraphy Devices Market Report 2025-2034 | Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape - GlobeNewswire Inc.
ResMed CFO Executes Stock Transaction Under Rule 10b5-1 Plan - TipRanks
ResMed CFO Brett Sandercock sells $891,285 in stock By Investing.com - Investing.com South Africa
Hedge Fund and Insider Trading News: Bill Ackman, Paul Tudor Jones, Chase Coleman, John Paulson, Polus Capital Management, VFC Corp (VFC), ResMed Inc (RMD), and More - Insider Monkey
ResMed CFO Brett Sandercock sells $891,285 in stock - Investing.com Australia
Equities Analysts Issue Forecasts for ResMed Q1 Earnings - Defense World
ResMed’s SWOT analysis: sleep tech giant faces growth challenges, new markets - Investing.com
ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Are Wall Street Analysts Bullish on ResMed Stock? - Inkl
Are Wall Street Analysts Bullish On ResMed Stock? - Barchart.com
Is it Worth Retaining ResMed Stock in Your Portfolio Now? - Nasdaq
Insider Sell: Witte De Sells 2,000 Shares of ResMed Inc (RMD) - GuruFocus
Why Kogan, Monash IVF, OFX, and ResMed shares are falling today - MSN
Resmed Inc (RMD) 財務データ
収益
当期純利益
現金流量
EPS
Resmed Inc (RMD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Farrell Michael J. | Chief Executive Officer |
Jun 09 '25 |
Sale |
251.21 |
8,009 |
2,011,910 |
455,503 |
0.13%
大文字化:
|
ボリューム (24 時間):